Fintech PR
Telix 2023 Full Year Results: Inaugural Profit Achieved, Strong Revenue Growth Underpins Investment in Late-stage Pipeline
MELBOURNE, Australia, Feb. 22, 2024 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its results for the financial year ended 31 December 2023. All figures are in AUD$ unless otherwise stated.[1]
2023 highlights
- Total Group revenue of $502.5M, an increase of 214% from $160.1M in 2022 primarily driven by continued strong growth in sales of Illuccix® in the second year since commercial launch (April 2022)
- Delivered positive adjusted earnings before interest, tax, depreciation, and amortisation (adjusted EBITDA) of $58.4M an increase of $126.2M, compared to a loss of $67.8M in 2022
- Inaugural full year profit of $5.2M after tax. A substantial improvement on the net loss after tax of $104.1M in 2022
- Investment in research and development (R&D) and selling, general and administration (SG&A) reflects progress across the late-stage pipeline and scale-up of the commercial organisation
- Overall operating costs as a percentage of revenue have reduced to 52% from 105% in 2022
- Gross margin has improved to 63% (vs. 59% in 2022) reflecting distribution and manufacturing costs optimisation
- Positive operating cash inflow in line with commercial sales growth, demonstrated through customer receipts of $463.7M (vs. $124.1M in 2022), and
- Closing cash balance was $123.2M as at 31 December 2023.
Progress across the core pipeline includes:
- First patients dosed in the ProstACT GLOBAL Phase III clinical trial of TLX591, a first-in-class investigational rADC[2] for prostate cancer therapy
- Positive interim readout from the ProstACT SELECT Phase I clinical trial reinforcing the differentiation of TLX591, including favourable safety profile and clinical utility of the patient-friendly short dosing regimen
- Submission of the Biologics License Application (BLA) for TLX250-CDx (Zircaix™[3]) to the United States Food and Drug Administration (U.S. FDA) for kidney cancer imaging on a rolling review basis
- Patients dosed in multiple clinical trials of Telix’s therapeutic candidate TLX250 for clear cell renal cell carcinoma (ccRCC) and other solid tumours expressing carbonic anhydrase IX (CAIX)
- First cohort of patients dosed in the IPAX-2 trial investigating Telix’s glioblastoma therapy candidate, TLX101, in newly diagnosed patients
- Commercialisation plans underway for glioma imaging agent, TLX101-CDx (Pixclara™[3]), ahead of the planned submission of a New Drug Application (NDA) to the U.S. FDA in Q1 2024, and
- Ethics approval granted to commence biodistribution and safety study of TLX300-CDx, first human study of radiolabelled olaratumab being developed as a therapeutic candidate for soft-tissue sarcoma.
Dr Christian Behrenbruch, Managing Director and Group CEO commented:
“This is an excellent result which demonstrates the strength of the Telix business model. We have achieved profitability while intensively investing in the development of our late-stage assets and the scale-up of our commercial infrastructure and marketing activity. This has resulted in Telix capturing a meaningful market share in the growing urology imaging market whilst laying the foundation for our next commercial products.
“We are highly focused on the development of our theranostic pipeline and vertical integration of supply and manufacturing. This activity is key to diversifying our revenue streams, creates additional value for our therapeutic assets and further differentiates Telix as a fully integrated global radiopharmaceutical company.”
Further details on the Company’s results can be found in the Appendix 4E, the accompanying investor presentation, and 2023 Annual Report lodged with the ASX and also available on the Company’s website.
Guidance
Full year revenue for 2024 expected range of US$445M to US$465M ($675M to $705M at current exchange rates), representing an approximate 35-40% increase on 2023.
Revenue guidance is based on worldwide sales of Illuccix®, with potential upside from Zircaix™[3] (kidney cancer imaging) and Pixclara™[3] (glioma imaging), subject to product regulatory approvals. Guidance will be updated throughout the year, as appropriate, to reflect product approvals.
Expected additional investment of 40-50% in R&D (compared with 2023), including both external and internal costs funded by operating cash flow and broadly in line with revenue growth.
2024 R&D investment activity is expected to include validation of commercial manufacturing and market launch activities in preparation for approval of Zircaix™[3] and Pixclara™[3] a fully operationalised ProstACT GLOBAL therapy trial in prostate cancer, and initiation of additional therapeutic clinical trials, including manufacturing activity, across the broader pipeline. 2024 R&D investment also includes indication expansion and life-cycle management of Illuccix®.
Investor call
An investor webcast will be held at 9.00am AEDT on Friday 23 February 2024 (Thursday 22 February 2024, 5.00pm EST)
Participants can register for the webcast and find audio call details at the following link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=Y7PkfQhS
About Telix Pharmaceuticals Limited
Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).
Visit www.telixpharma.com for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on X and LinkedIn.
Telix’s lead imaging product, gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the U.S. Food and Drug Administration (FDA),[4] by the Australian Therapeutic Goods Administration (TGA),[5] and by Health Canada.[6] Telix’s miniaturised surgical gamma probe, SENSEI®, for minimally invasive and robotic-assisted surgery, has attained a marketing authorisation in the U.S., having been registered with the FDA and has attained a Conformité Européenne (CE) Mark for use in the European Economic Area for the intra-operative detection of sentinel lymph nodes (SLNs). With the exception of Illuccix® and SENSEI® as noted above, no Telix product has received a marketing authorisation in any jurisdiction.
Full United States prescribing information for Illuccix® can be found at: http://illuccixhcp.com/s/illuccix-prescribing-information.pdf
Telix Investor Relations
Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: [email protected]
This announcement including earnings guidance has been authorised for release by the Telix Pharmaceuticals Limited Board.
Legal Notices
The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained in this document or opinions expressed in the course of this announcement. The information contained in this announcement is subject to change without notification.
This announcement may contain forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “outlook”, “forecast” and “guidance”, or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect the Company’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical studies, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix’s product candidates, if or when they have been approved; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the ASX or on our website.
To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to publicly update or revise any forward-looking statements contained in this announcement, whether as a result of new information, future developments or a change in expectations or assumptions.
Telix uses various non-IFRS information to reflect its underlying performance. For further information, the reconciliation of non-IFRS financial information to Telix’s statutory measures, reasons for usefulness and calculation methodology, please refer to the Alternative performance measures section in Telix’s Annual Report.
©2024 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals and Illuccix®, Pixclara™,[3] Zircaix™[3] and SENSEI® names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.
|
[1] Conversion to AUD$ is at the exchange rate on the relevant transaction date. The average exchange rate realised during the period was AUD$1 = US$0.66; AUD$1 = €0.54. |
|
[2] Radio antibody-drug conjugate. |
|
[3] Trade name subject to final regulatory approval. |
|
[4] Telix ASX disclosure 20 December 2021. |
|
[5] Telix ASX disclosure 2 November 2021. |
|
[6] Telix ASX disclosure 14 October 2022. |
Logo – https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/telix-2023-full-year-results-inaugural-profit-achieved-strong-revenue-growth-underpins-investment-in-late-stage-pipeline-302068547.html
The promotions span across six practice areas and three regions to drive growth in 2025 and beyond
CHICAGO, Jan. 6, 2025 /PRNewswire/ — Heidrick & Struggles (Nasdaq: HSII), a premier provider of global leadership advisory and on-demand talent solutions, today announced key global and regional leader appointments, effective January 1, 2025. The appointed leaders will continue advancing the firm’s objective of delivering exceptional value to clients by fostering differentiated, deep, and durable relationships.
“Having the right leadership in place is increasingly crucial to business performance, growth, and prosperity, making our work more important than ever,” said Tom Monahan, CEO, Heidrick & Struggles. “This dynamic group embodies our values as a firm as well as our unwavering commitment to delivering superior client service. We’re excited to promote these outstanding leaders as they continue to shepherd our clients through their most pressing business and talent challenges.”
These leaders span Heidrick & Struggles’ priority practice and solution areas, as well as multiple regions globally.
Individuals appointed to Regional Leader:
- Anne Rockey, North America
- Richard Guest, Asia Pacific & Middle East
Individual appointed to Global Managing Partner:
- Todd Taylor, Client Driven Growth, a newly created role
Individuals appointed to Executive Search Global Practice Managing Partner:
- Jaimee Eddington, Corporate Officers Practice
- Dominique Fortier, Financial Services Practice
- Chris Bray, Global Technology & Services Practice
- Gustavo Alba, Co-Lead, Private Equity Practice
Individuals appointed to Executive Search Regional Practice Managing Partner:
- Liz Langel, Americas, Financial Services Practice
- Ina Sood, Americas, Healthcare & Life Sciences Practice
- David Burd, Americas, Corporate Officers Practice
- David Crawford, Asia Pacific & Middle East, Global Technology & Services Practice
- Tom Cunningham, Europe & Africa, Global Technology & Services Practice
- Sarah Driscoll, Europe & Africa, Global Technology & Services Practice
- Roman Wecker, Europe & Africa, Industrial Practice
Individuals appointed to Partner-in-Charge:
- Jane Xing, Beijing
- Jessi Gentile, Chicago
- Maliha Jilani, Dubai
- Kim Pomoell, Finland
- Kiwook Kim, Korea
- David Richardson, New York/Stamford
- Christina Besozzi Cary, Washington, D.C.
Individual promoted in Heidrick Consulting:
- Eric Joseph, leading North America on an interim basis
About Heidrick & Struggles
Heidrick & Struggles (Nasdaq: HSII) is a premier provider of global leadership advisory services and on-demand talent solutions, serving the senior talent and consulting needs of the world’s top organizations. Heidrick & Struggles pioneered the profession of executive search more than 70 years ago. Today, we partner with clients to develop future-ready leaders and organizations, combining our expertise in executive search, leadership consulting, and on-demand, critical talent solutions to achieve the highest levels of profitability and performance. Helping our clients change the world, one leadership team at a time.® www.heidrick.com
Media Contact
Bianca Wilson
Global Director, Public Relations
Heidrick & Struggles
[email protected]
Logo – https://mma.prnewswire.com/media/139029/heidrick_struggles_logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/heidrick–struggles-announces-2025-global-and-regional-leader-appointments-302343456.html
LONDON, Jan. 6, 2025 /PRNewswire/ — Finastra, a global provider of financial services software applications, today announced a significant leadership transition. After nearly a decade of transformative leadership, Simon Paris will step down from his role as Chief Executive Officer. Chris Walters has joined Finastra and will assume the role of Chief Executive Officer.
Chris brings a wealth of experience from senior executive leadership positions, driving innovation and scaling technology companies. He recently served as CEO of Pluralsight and Avantax, a leading company within Financial Services, where he orchestrated significant performance improvement and the company’s successful sale. Prior to Pluralsight and Avantax, Chris served in a variety of leadership roles, including being a Partner at McKinsey & Company and the COO of Bloomberg Industry Verticals Group.
On his appointment, Chris said, “I’m excited to join Finastra at this pivotal moment in its journey and am impressed by the significant progress that has been made during Simon’s leadership. I look forward to working with the talented team to drive sustainable growth and continue to deliver more value to our customers, team members, and investors.”
Under Simon’s stewardship, the company has achieved remarkable milestones, including:
- Leading the charge in Open Finance, following the merger of Misys and D+H in 2017 to form Finastra
- Building a loyal customer base of over 8,000 clients in 130 countries, including 45 of the world’s top 50 banks
- Achieving recognition as a leader in Generative AI, with all employees upskilled and ~50 capabilities in progress from ideation to production stages
- Garnering extensive market accolades, including multiple product, culture, and leadership awards, and being named the #1 Banking Technology company, the #2 Financial Technology company, and appearing in the top 15 Software companies worldwide in 2024 alone
- Delivering record financial performance and double-digit Annual Recurring Revenue (ARR) growth
As Finastra embarks on its new strategic sprint in 2025, the company is well-positioned for continued success. During the transition period, Simon and Chris will work closely together to ensure a smooth handover.
Simon reflected on his tenure, saying, “This journey with Finastra has been a privilege. Chris is a seasoned professional, and I am honored to ‘pass the baton’ to him. I leave incredibly proud of what Finastra has achieved so far and excited for the company’s future under Chris’s leadership.”
About Finastra
Finastra is a global provider of financial services software applications across Lending, Payments, Treasury and Capital Markets, and Universal (retail and digital) Banking. Committed to unlocking the potential of people, businesses and communities everywhere, its vision is to accelerate the future of Open Finance through technology and collaboration, and its pioneering approach is why it is trusted by ~8,100 financial institutions, including 45 of the world’s top 50 banks. For more information, visit finastra.com.
Photo – https://mma.prnewswire.com/media/2591526/Simon_Paris_and_Chris_Walters.jpg
Logo – https://mma.prnewswire.com/media/1916021/5100855/FINASTRA_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/finastra-announces-leadership-transition-welcoming-chris-walters-as-new-ceo-302343232.html
AI Impact leverages DXC’s combined consulting, engineering, and secure enterprise services
ASHBURN, Va., Jan. 6, 2025 /PRNewswire/ — DXC Technology (NYSE: DXC), a leading Fortune 500 global technology services provider, today announced AI Impact, an approach designed to help solve customers’ most pressing challenges. By combining DXC consulting, engineering and secure enterprise services, DXC will help clients across industries securely innovate and drive real business outcomes with AI.
DXC takes a pragmatic approach to AI by focusing on developing solutions that solve real world challenges and support business growth. With DXC’s AI Impact, customers benefit from DXC’s vast industry expertise and technology experience to build solutions, services and experiences together that will deliver real business outcomes using the latest technology innovation. Read more about DXC’s approach here.
“AI has already captured the attention and imagination of industries everywhere. From AI agents to autonomous driving and personalized medicine, companies are taking steps to unlock value from AI, which promises to reshape our world,” said Howard Boville, EVP, Consulting & Engineering Services – Powered by AI. “With DXC’s AI Impact approach, we are helping to push the boundaries of what AI makes possible, guided by our team of consulting, engineering and technology experts to address our clients’ most pressing challenges.”
Customers across industries are leveraging AI Impact, including:
- Automotive: DXC is helping customers leverage AI-powered diagnostic tools to make it easier for automotive manufacturers and service providers to identify potential issues before they become critical, reducing downtime and maintenance costs. DXC is also helping customers leverage AI to personalize every aspect of a vehicle, including personal assistants that learn a driver’s preferences and habits over time to make more intuitive recommendations.
- Public Sector: To provide more transparency, governments are using DXC AI Impact to efficiently engage with citizens and make it easier for them to access public services. This includes the use of AI Agents and AI enhanced processes that streamline and simplify tax, national lending and even public healthcare processes.
- Financial Services and Insurance: DXC is helping customers optimize operations, from underwriting and risk assessment to claims processing and customer service. By working with DXC, financial institutions are leveraging chatbots to make it easy for human agents to respond faster and more accurately to customer inquiries by analyzing thousands of documents in minutes with Generative AI.
- Healthcare: DXC implemented an AI-powered app to help measure patient symptoms in real-time, analyzing data to provide clinicians with insights that enable more accurate diagnoses and treatment plans, improving the quality of care and proactively addressing prescription resistance.
For more information on DXC AI Impact and how we’re working with the most innovative industry leaders to securely innovate, visit here.
Forward Looking Statements
All statements in this press release that do not directly and exclusively relate to historical facts constitute “forward-looking statements.” These statements represent current expectations and beliefs, and no assurance can be given that any result, goal or plan set forth in any forward-looking statement can or will be achieved. Such statements are subject to numerous assumptions, risks, uncertainties and other factors that could cause actual results to differ materially from those described in such statements, many of which are outside of our control. For a written description of these factors, see the section titled “Risk Factors” in DXC’s Annual Report on Form 10-K for the fiscal year ended March 31, 2024, and any updating information in subsequent SEC filings. Readers are cautioned not to place undue reliance on such statements which speak only as of the date they are made. We do not undertake any obligation to update or release any revisions to any forward-looking statement or to report any events or circumstances after the date of this document or to reflect the occurrence of unanticipated events, except as required by law.
About DXC Technology
DXC Technology (NYSE: DXC) helps global companies run their mission-critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. The world’s largest companies and public sector organizations trust DXC to deploy services to drive new levels of performance, competitiveness, and customer experience across their IT estates. Learn more about how we deliver excellence for our customers and colleagues at DXC.com.
CONTACT: Mihir Bellamkonda, Media Relations, [email protected]; Roger Sachs, Investor Relations, [email protected]
View original content:https://www.prnewswire.co.uk/news-releases/dxc-technologys-ai-impact-helps-customers-across-industries-innovate-with-ai-302343102.html
-
Fintech PR6 days agoOutsourced Accounting Service: The New Standard for Business Finance Industry
-
Fintech PR6 days agoBybit Launchpad Onboards Xterio, Opening up Opportunities in Blockchain Gaming for Users
-
Fintech PR6 days agoCKGSB Professor Mei Jianping Launches Global Indices Tracking Impressionist, Contemporary, and Chinese Art Markets
-
Fintech PR6 days agoIBN Technologies Sets the Benchmark in Financial Management Accounting Excellence
-
Fintech PR3 days agoBybit x Block Scholes Report: BTC Options Steady with Call-Put Parity, ETH Braces for Short-Term Volatility
-
Fintech PR6 days agoDayOne Launches as an Independent Global Data Center Pioneer Following Series B Funding Closure
-
Fintech PR6 days agoGES Completes Sale to Truelink Capital
-
Fintech PR3 days agoArtificial Intelligence (AI) in Trading Market to Reach USD 35 Billion by 2030, Growing at a 10% CAGR | Valuates Reports